文献速递临床试验与 GCP基础与转化研究

渴络欣胶囊联合氯沙坦钾治疗糖尿病肾病:随机双盲安慰剂对照多中心临床试验方案

Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
PubMed 文献 · Trials · 2020-11-23

本研究为随机双盲安慰剂对照多中心试验,计划纳入252例糖尿病肾病患者,随机分为氯沙坦钾联合渴络欣胶囊组或联合安慰剂组,治疗24周。主要结局为eGFR下降值,次要结局包括血清肌酐加倍、终末期肾病、eGFR进展性下降>30%比例、24小时尿蛋白变化等。

要点

  • 渴络欣胶囊联合氯沙坦钾可能优于单用氯沙坦钾治疗糖尿病肾病。
  • 主要结局指标为24周内eGFR下降值(ml/min/1.73 m2/year)。
  • 试验为随机双盲安慰剂对照多中心设计,来自18家机构。

核心结论

  • 该试验旨在评估渴络欣胶囊联合氯沙坦钾是否比单用氯沙坦钾更有效治疗糖尿病肾病,并为渴络欣胶囊的应用提供验证证据。

研究设计与样本

  • 随机双盲安慰剂对照多中心临床试验,计划从18家机构招募252例糖尿病肾病患者。
  • 参与者随机分配至氯沙坦钾联合渴络欣胶囊组(n=126)或氯沙坦钾联合安慰剂组(n=126),治疗24周。

关键数值与推荐

  • 主要结局为24周内eGFR从基线的下降值(ml/min/1.73 m2/year)。
  • 次要结局包括血清肌酐加倍发生率、终末期肾病发生率、eGFR进展性下降>30%的受试者比例、24小时尿总蛋白百分比变化、尿白蛋白/肌酐比值变化及中医证候量表评分总有效率。
  • 组间变量差异比较采用独立t检验、卡方检验、Fisher精确检验或Wilcoxon检验,所有统计检验为双侧,p值<0.05认为显著。

临床怎么用

  • 该试验结果将为糖尿病肾病患者处方渴络欣胶囊提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetic kidney disease (DKD) is one of the most important microvascular complications of diabetes, and its prevalence has increased dramatically in the past few decades. DKD is responsible for considerable morbidity and mortality of patients with diabetes. Keluoxin capsule (KLX) is a Chinese patent medicine that has been used in the clinic to control DKD for years. Previous studies have shown that KLX appears to reduce proteinuria, but the study protocols as well as the primary outcome need to be improved. Thus, we aim to evaluate whether losartan potassium combined with KLX is more effective than losartan potassium in DKD treatment and to provide validated evidence for the application of KLX in the treatment of DKD. METHODS: We will conduct a randomized double-blind placebo-controlled multicenter clinical trial. A total of 252 participants diagnosed with DKD recruited from 18 institutions will be randomly allocated to either a losartan potassium plus KLX (n = 126) or a losartan potassium plus placebo group (n = 126). The participants will be administered KLX or placebo in addition to losartan potassium for 24 weeks. The primary outcome measure will be the decline in estimated glomerular filtration rate (eGFR) (ml/min/1.73 m2/year) from baseline within 24 weeks, and the secondary outcomes will be the incidence of serum creatinine doubling, the incidence of end-stage renal disease (ESRD), the proportion of subjects with a progressive decline in eGFR > 30%, the percent change in 24 h urinary total protein (UTP), the change in the urinary albumin/creatinine ratio (UACR), and the total effective rate of the traditional Chinese medicine (TCM) syndrome scale scores. Comparison of the differences in the variables between groups will be performed according to the data revealed by independent t tests, chi-squared tests, Fisher's exact tests, or Wilcoxon's tests. All statistical tests will be two-sided, and significance will be considered for p values < 0.05. DISCUSSION: This study will be the first randomized clinical trial to evaluate the efficacy and safety of KLX versus the placebo for the treatment of patients with DKD. The outcome of this trial will provide a basis for prescribing KLX to patients with DKD. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( www.chictr.org.cn ) ChiCTR1900021113. Registered on January 29, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wu R, Wei F, Qu L, et al. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial. Trials. 2020. PMID: 33228726. doi:10.1186/s13063-020-04852-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。